Terry Onichi Matsunaga

Tucson, AZ, United States of America

Terry Onichi Matsunaga

This inventor holds 25 USPTO granted patents and 5 published patent applications, primarily in Therapeutic Delivery Systems. Top assignees: Imarx Pharmaceutical Corporation, The University of Arizona, Bristol-Myers Squibb Medical Imaging, Inc.. Active years: 1995-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Terry Onichi Matsunaga. Retrieved from https://idiyas.com/inventor/terry-onichi-matsunaga

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 25 

% Patents Active = 96.0

Average Co-Inventor Count = 4.4

ph-index = 20

Forward Citations = 3,339(Granted Patents)


Company Filing History:


Years Active: 1995-2026

Loading Chart...
Areas of Expertise:
Nanodroplet
Acoustically Activatable Particles
Phase Change Conjugates
Diagnostic Imaging
Therapeutic Delivery
Gas-Filled Liposomes
Microspheres
Targeted Compositions
Multi-Phase Composition
Fluorinated Gas
Lipid Spheres
Gaseous Precursors
25 patents (USPTO):Explore Patents

Title: **Innovator Spotlight: Terry Onichi Matsunaga**

Introduction

Terry Onichi Matsunaga is an accomplished inventor based in Tucson, Arizona, known for her significant contributions to innovative technologies in the field of acoustically activatable particles and targeted delivery systems. With an impressive portfolio of 24 patents, her work demonstrates a commitment to advancing medical and pharmaceutical applications through her inventive solutions.

Latest Patents

Among Matsunaga's latest breakthroughs are two noteworthy patents. The first is a formulation of acoustically activatable particles that possess low vaporization energy, which includes particles encapsulating a substance with a boiling point below 25°C at atmospheric pressure. This innovative design features a polymeric brush layer to prevent aggregation and enhance stability.

The second patent is focused on phase change nanodroplet conjugates for targeted delivery. These conjugates consist of a nanodroplet containing a gaseous precursor, enveloped by an outer shell, which may be a lipid monolayer, lipid bilayer, or polymer layer. They ingeniously allow for the attachment of therapeutic, prophylactic, or diagnostic nanoparticles, facilitating targeted drug delivery through ultrasonic stimulation that prompts vaporization and subsequent drug release.

Career Highlights

Matsunaga has held positions at esteemed organizations such as Imarx Pharmaceutical Corporation and the University of Arizona. Her expertise in the development of acoustically driven technologies has paved the way for new treatment modalities in healthcare. Her dedication to her field reflects not only in her patents but also through her continued research and innovation.

Collaborations

Throughout her career, Matsunaga has collaborated with distinguished colleagues including Evan C. Unger and David W. Yellowhair. These partnerships highlight her ability to work within diverse teams to enhance the impact of her innovative ideas on medical technologies.

Conclusion

Terry Onichi Matsunaga exemplifies the spirit of innovation through her commitment to developing new technologies that enhance medical treatments. With her 24 patents and ongoing collaborations, Matsunaga continues to inspire future generations of inventors and contribute significantly to the scientific community. Her work stands as a testament to the power of innovation in transforming healthcare solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…